Sellas Life Sciences presents Phase 3 data showing GPS reduces death risk 41% in AML patients
SLS•Sellas Life Sciences said galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint, reducing death risk by 41% in AML patients in second remission. Median overall survival was 24.0 months versus 14.7 months with best available treatment; the company plans to meet with the FDA and prepare an expedited biologics license application.
1. REGAL trial results
Sellas Life Sciences said galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint in AML patients in second remission, reducing death risk by 41%. Median overall survival was 24.0 months with galinpepimut-S and 14.7 months with best available treatment; the hazard ratio was 0.59, with statistical significance at p=0.035. The company plans to meet with the FDA while preparing an expedited biologics license application. Sellas also said SLS009 met all primary endpoints in its completed Phase 2 study in relapsed or refractory AML.




